Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04667234
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2023-09-28
First Post:
2020-12-08
Brief Title:
Expanded Access of Sotorasib
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multicenter Open-label Single-arm Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced UnresectableMetastatic NSCLC With KRAS pG12C Mutation
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to provide expanded access to and characterize the safety profile of Sotorasib in participants with previously treated locally advancedunresectablemetastatic non small-cell lung cancer NSCLC with KRAS pG12C mutation in a real-world setting
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None